Recently, Starry Pharma has proudly announced the successful closure of its Series B funding round, amassing an impressive sum exceeding RMB 300 million. This pivotal financing endeavor was co-led by LYFE Capital, Hillhouse Venture Capital, and Lilly Asia Ventures, with continued support from existing investors. The proceeds from this round will be strategically allocated to enhance and expand the company's extrahepatic targeted delivery platform, expedite the clinical progression of in vivo cell therapy pipelines, and fortify its innovative strategic positioning within the realm of RNA therapeutics.

Established in August 2021, Starry Pharma has carved out a niche for itself by specializing in extrahepatic targeted delivery technologies, backed by a highly competent core team. The company has meticulously constructed a cutting-edge library of cationic lipid molecules, identified multiple lipid nanoparticles through rigorous screening, and established comprehensive research, development, and pilot-scale production capabilities, enabling the development of diverse dosage forms.

In a mere two years since its inception, Starry Pharma has not only secured substantial funding in the hundreds of millions of yuan but also amassed a rich R&D pipeline. Multiple projects are currently progressing through the preclinical and IND (Investigational New Drug) application phases. Among its notable achievements, the company's mRNA vaccine targeting respiratory syncytial virus has garnered FDA clinical trial approval, with experiments slated to commence in 2024.